Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Raghav Gulati takes a one-shot lead with an impressive five-under-par 67 on Day One of the Tommy Fleetwood Pathway Series at ...

February's Full Moon, or Snow Moon, is a potent time for aligning with your deepest desires. Engaging with its energy supports reflection, intention-setting, and manifestation. The article provides ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Six Democratic candidates vying for New Jersey’s governorship spoke directly to voters at the first debate of the season ...

New Jersey Democratic gubernatorial candidates vowed to protect illegal immigrants from President Trump’s ICE raids during ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Six candidates for the Democratic nomination for governor assembled at Rider University for a debate Sunday night. What did ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...